RadNet Q4 Topline, BottomLine Hit Due To Omicron Surge, FY22 Guidance In-Line With Consensus

  • RadNet Inc RDNT reports Q4 FY21 revenue of $333.2 million, +8% Y/Y, missing the consensus of $348.34 million.
  • Aggregate procedural volumes increased 11.4%; Same-center procedural volumes increased 7.3% Y/Y.
  • RadNet's adjusted EBITDA grew 7.5% Y/Y to $54.5 million.
  • The Company posted an adjusted EPS of $0.13, lower than $0.20 a year ago and missing the consensus of $0.19.
  • Howard Berger, President & CEO, said that an 8% increase in Q4 sales resulted from ongoing strong demand for services and the continuing migration of patient procedures from hospitals to free-standing ambulatory outpatient imaging centers. 
  • The Company noted that improvement in operating metrics during the quarter overshadowed the negative impact from the omicron surge, which reduced the revenue by over $4 million and adjusted EBITDA by approximately $3 million.
  • Guidance: RadNet expects FY22 sales of $1.35 billion - $1.4 billion, versus the consensus of $1.4 billion.
  • It expects an adjusted EBITDA of $205 million - $215 million.
  • Price Action: RDNT shares closed higher by 1.31% at $24.67 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!